Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Choosing drug therapy for multiple sclerosis. An update

B W van Oosten1, L Truyen, F Barkhof

  • 1Department of Neurology, Free University Hospital, Amsterdam, The Netherlands.

Drugs
|November 7, 1998
PubMed
Summary

Multiple sclerosis (MS) is an immune disorder affecting the central nervous system. Current treatments focus on managing relapses with methylprednisolone and preventing them with interferons or glatiramer acetate, while research explores new therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

What if it is the eyes? The effect of eye movement disorders on cognitive testing in MS.

Journal of neurology·2026
Same author

Reliability of serum neurofilament light and glial fibrillary acidic protein for detecting disease activity upon discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS).

Journal of neurology·2025
Same author

The recurrence of disease activity after ocrelizumab discontinuation in multiple sclerosis.

Multiple sclerosis and related disorders·2024
Same author

Influence of personalized extended interval dosing on the natalizumab wearing-off effect - a sub-study of the NEXT-MS trial.

Journal of the neurological sciences·2024
Same author

Diffuse alveolar hemorrhage as an early complication of alemtuzumab treatment: A case report of a multiple sclerosis patient and an overview of 14 cases.

Multiple sclerosis and related disorders·2020
Same author

A tumefactive demyelinating lesion in a person with MS after five years of fingolimod.

Multiple sclerosis and related disorders·2020

Area of Science:

  • Neuroimmunology
  • Neurology

Background:

  • Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system.
  • MS is characterized by relapses and remissions, often progressing to chronic disability.
  • Neurological symptoms arise from inflammation and demyelination in the CNS white matter.

Purpose of the Study:

  • To review current and emerging treatment strategies for multiple sclerosis.
  • To discuss the efficacy of existing therapies for different MS disease courses.
  • To highlight the importance of symptomatic management and rehabilitation.

Main Methods:

  • Review of current medical literature on multiple sclerosis treatments.
  • Analysis of therapeutic options for relapsing-remitting and progressive MS.

Related Experiment Videos

  • Discussion of immunomodulatory and remyelinating strategies.

    • Main Results:

    • High-dose intravenous methylprednisolone is effective for acute MS relapses.
    • Interferon-beta-1a/1b partially prevent relapses in relapsing-remitting MS.
    • Glatiramer acetate shows potential efficacy; methotrexate may be considered for rapidly progressive MS.

    Conclusions:

    • Symptomatic treatment and multidisciplinary rehabilitation are crucial for most MS patients.
    • Emerging therapies aim to target immune mechanisms and promote remyelination.
    • Further research is needed to establish treatment efficacy in progressive MS forms.